Centogene and Anylam launch clinical programme
Diagnostics developer Centogene NV and Alnylam Pharmaceuticals launched a clinical programme aimed at improving ATTRv diagnosis.
Avantium NV bags money for demo plant
Green chemistry company Avantium NV has secured a 7.5m funding from the National Programme Groningen to support the construction of a 5 kilotonnes FDCA plant.
How stress brings cancer to life again
Swiss Noema Pharma raises CHF54m in Series A financing
Noema Pharma AG kicks off with CHF54m and licenced drug candidates from Roche AG.
Germany first EU country to launch COVID-19 therapy offensive?
After months of lobbying by the BIOM biotech cluster, Bavaria is launching a 50m initiative to push the best and fastest COVID-19 therapies.
Moderna to file for EU approval of mRNA-1273 vaccine
COVID-19 mRNA vaccine developer Moderna Inc reported it will file for FDA and EMA authorisation of mRNA-1273 based on Phase III results.
Drug set to rescue COVID-19 patients at ICUs
Aviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients.
Polyphor AG bags funding for murepavadin
Polyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.
EU COVID-19 antibody ready for clinical trials
As investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing.
COVID-19: Moderna reports promising interim results
After BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.